中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2013, Vol. 8 ›› Issue (23): 2144-2154.doi: 10.3969/j.issn.1673-5374.2013.23.004

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

急性脑梗死患者治疗中阿托伐他汀的抗炎抗栓效应

  

  • 收稿日期:2013-03-07 修回日期:2013-06-09 出版日期:2013-08-15 发布日期:2013-08-15

Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke

Lianqiu Min1, Shuai Shao2, Xiaoning Wu1, Lin Cong3, Ping Liu4, Haiping Zhao4, Yumin Luo4   

  1. 1 Department of Neurology, First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, Liaoning Province, China
    2 Department of Neurology, Liaoyang Central Hospital, Liaoyang 111000, Liaoning Province, China
    3 Department of Neurology, Fuxin No.2 People’s Hospital, Fuxin 123000, Liaoning Province, China
    4 Research Institute of Cerebrovascular Diseases, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
  • Received:2013-03-07 Revised:2013-06-09 Online:2013-08-15 Published:2013-08-15
  • Contact: Lianqiu Min, Master, Professor, Chief physician, Department of Neurology, First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, Liaoning Province, China, minlianqiu@163.com.
  • Supported by:

    辽宁省科学自然基金 (No.20092192)，国家自然科学基金 (No.81071058)

PDF

1741

摘要：

阿托伐他汀可减轻颈动脉斑块患者的炎症及血栓形成，但其作为降脂药物其抗炎及抗栓作用机制仍不清。将来自中国辽宁地区大动脉粥样硬化性急性脑梗死患者89例随机分为2组，均采用常规抗血小板、改善循环及对症等治疗，其中治疗组43例口服阿托伐他汀20 mg/d治疗，对照组46例口服等剂量淀粉片。血清学指标检测及相关性分析结果显示，阿托伐他汀治疗4周后，患者血清C-反应蛋白、纤维蛋白原、D二聚体较安慰剂组明显降低；血清C-反应蛋白、纤维蛋白原、D二聚体水平降低与三酰甘油，低密度脂蛋白胆固醇水平降低无相关性。结果证实，阿托伐他汀可减轻中国辽宁地区大动脉粥样硬化性急性脑梗死患者的炎症和血栓水平，具有独立于调脂作用之外的抗炎抗栓作用。

关键词: 神经再生, 脑损伤, 脑梗死, 大动脉粥样硬化, 阿托伐他汀, C-反应蛋白, 纤维蛋白原, D-二聚体, 炎症, 血栓, 甘油三酯, 低密度脂蛋白胆固醇, 基金资助文章

Abstract:

Atorvastatin decreases inflammation and thrombogenesis in patients with carotid artery plaque. Atorvastatin is administered to lower lipid levels, but its anti-inflammatory and anti-thrombogenic effects remain unclear. Eighty-nine patients from northeastern China with acute ischemic stroke caused by large-artery atherosclerosis were randomly divided into the study and control groups. All patients received routine treatment, including antiplatelet therapy, circulatory support, and symp-tomatic treatment. The study group (n = 43) also received daily atorvastatin 20 mg/d, and the control group (n = 46) received daily placebo pills containing glucose. After 4 weeks, the levels of C-reactive protein, fibrinogen, and D-dimer were significantly lower in the study group than in the control group. Decreases in the levels of C-reactive protein, fibrinogen, and D-dimer were not associated with de-creases in the levels of triacylglycerol and low-density lipoprotein cholesterol. These results suggest that atorvastatin reduces inflammation and thrombogenesis independent of its lipid-lowering effects in patients with acute ischemic stroke caused by large-artery atherosclerosis.

Key words: neural regeneration, brain injury, ischemic stroke, large-artery atherosclerosis, atorvastatin, C-reactive protein, fibrinogen, D-dimer, inflammation, thrombus, triacylglycerol, low-density lipo-protein cholesterol, grants-supported paper, neuroregeneration